

Pharmacokinetic Interactions Between Bazedoxifene and Cholecalciferol: An Open-Label, Randomized, Crossover Study in Healthy Male Volunteers

Moon Hee Lee¹, Seok-Kyu Yoon¹, Hyungsub Kim², Yong-Soon Cho³, Sungpil Han⁴, Shi Hyang Lee¹, Kyun-Seop Bae¹, Jina Jung⁵, Sung Hee Hong⁵, Hyeong-Seok Lim¹

¹Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea; ²Department of Emergency Medical Services, College of Health Sciences, Eulji University, Seongnam, Republic of Korea; ³Department of Pharmacology and Clinical Pharmacology, Inje University College of Medicine, Busan, Republic of Korea; ⁴Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; ⁵Hanmi Pharmaceutical Co. Ltd., Seoul, Republic of Korea

Correspondence: Hyeong-Seok Lim, Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea, Tel +82-2-3010-4613, Fax +82-2-3010-4623, Email mdlhs@amc.seoul.kr

Purpose: The combined administration of bazedoxifene, a tissue-selective estrogen receptor modulator, and cholecalciferol can be a promising therapeutic option for postmenopausal osteoporosis patients. This study aimed to examine the pharmacokinetic interactions between these two drugs and the tolerability of their combined administration in healthy male subjects.

Patients and Methods: Thirty male volunteers were randomly assigned to one of the six sequences comprised of three treatments: bazedoxifene 20 mg monotherapy, cholecalciferol 1600 IU monotherapy, and combined bazedoxifene and cholecalciferol therapy. For each treatment, a single dose of the investigational drug(s) was administered orally, and serial blood samples were collected to measure the plasma concentrations of bazedoxifene and cholecalciferol. Pharmacokinetic parameters were calculated using the non-compartmental method. The point estimate and 90% confidence interval (CI) of the geometric mean ratio (GMR) were obtained to compare the exposures of combined therapy and monotherapy. The pharmacokinetic parameters compared were the maximum plasma concentration (C_{max}) and the area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC_{last}). The safety and tolerability of the combined therapy were assessed in terms of the frequency and severity of adverse events (AEs).

Results: For bazedoxifene, the GMR (90% CI) of the combined therapy to monotherapy was 1.044 (0.9263–1.1765) for C_{max} and 1.1329 (1.0232–1.2544) for AUC_{last} . For baseline-adjusted cholecalciferol, the GMR (90% CI) of the combined therapy to monotherapy was 0.8543 (0.8005–0.9117) for C_{max} and 0.8056 (0.7445–0.8717) for AUC_{last} . The frequency of AEs observed was not significantly different between the combined therapy and monotherapy, and their severity was mild in all cases.

Conclusion: A mild degree of pharmacokinetic interaction was observed when bazedoxifene and cholecalciferol were administered concomitantly to healthy male volunteers. This combined therapy was well tolerated at the dose levels used in the present study.

Keywords: bazedoxifene, cholecalciferol, drug-drug interaction, pharmacokinetics, tolerability

Introduction

Osteoporosis is a skeletal disorder characterized by low bone mass and an increased risk of bone fracture. Bone mass reaches its peak in young adulthood, and increased bone resorption relative to bone formation leads to the lowering of bone mass. According to the World Health Organization, osteoporosis is defined as hip or lumbar spine bone marrow density of more than 2.5 standard deviations below the mean found in the young-adult population.¹ Osteoporosis is a significant public health concern among the elderly due to the increased morbidity and mortality associated with bone fractures. It affects both sexes and all races, and its prevalence is expected to rise as the global population continues to age.¹



The pharmacologic agents for the prevention and treatment of osteoporosis include calcium, vitamin D, bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulator (SERM), parathyroid hormone, and anti-receptor activator of nuclear factor-kappa B ligand antibody (denosumab).² The therapeutic potential of new treatment approaches, such as exosomes derived from endothelial cells or mesenchymal stem cells, has been investigated recently in animal models.^{3,4}

Bazedoxifene, a third-generation SERM, exhibits tissue-selective action, functioning as an agonist in skeletal tissue but as an antagonist in breast and uterine tissues.^{5,6} Bazedoxifene has been approved for the treatment of postmenopausal osteoporosis by the European Medicines Agency, and conjugated estrogens/bazedoxifene have been approved for the prevention of postmenopausal osteoporosis by the United States Food and Drug Administration.^{7,8} Cholecalciferol, commonly known as vitamin D₃, plays an important role in bone metabolism. Cholecalciferol is converted to calcifediol (25-hydroxycholecalciferol) in the liver and then to calcitriol (1,25-dihydroxycholecalciferol), the active form of vitamin D, in the kidney. Although vitamin D can be obtained from dietary intake and synthesized in the skin after exposure to sunlight, its deficiency is common. The National Osteoporosis Foundation recommends 800–1000 IU of vitamin D intake per day for individuals aged 50 and older.¹

A fixed-dose combination formulation of bazedoxifene and cholecalciferol is a potentially promising therapeutic option for postmenopausal osteoporosis patients as it can improve treatment efficacy and medication compliance. Before developing a fixed-dose combination formulation, the pharmacokinetic (PK) interactions between bazedoxifene and cholecalciferol need to be assessed. This study aimed to examine the PK interactions between these drugs as well as their safety and tolerability when co-administered in healthy male subjects.

Materials and Methods

Study Design

The study was designed as an open-label, randomized, three-period, three-treatment, six-sequence, crossover clinical trial. Healthy male volunteers aged between 19 and 40 years with body mass index (BMI) between 19 and 28 kg/m² were eligible for inclusion. Subjects were screened based on past medical history, physical examination including vital signs (blood pressure, heart rate, and body temperature), urine drug screening, clinical laboratory tests, serology tests, and 12-lead electrocardiogram (ECG). Subjects with a history of venous thromboembolism, hypercalciuria, renal stone, hepatobiliary disease, galactose intolerance, drug abuse, or clinically significant hypersensitivity reaction were excluded.

A total of 30 subjects were randomly assigned to six sequences comprised of three treatments: one tablet of 20 mg bazedoxifene (Viviant[®]; Pfizer Ltd., Seoul, Korea), two tablets of 800 IU cholecalciferol (HGP1501; Hanmi Pharmaceutical Co. Ltd., Seoul, Korea), or one tablet of 20 mg bazedoxifene along with two tablets of 800 IU cholecalciferol (Table 1). Outpatient visits were scheduled on day –10 of period 1 and day –9 of periods 2 and 3. At that time, subjects were provided with sunscreens (sun protection factor 50) and diaries to record their diet and activity. Subjects were asked to limit their exposure to sunlight by applying sunscreen and covering themselves with clothes and hats for outdoor activities. Subjects were required to refrain from taking dietary supplements and foods high in vitamin

Table 1 Overall Study Design

Sequence	Period 1	Period 2	Period 3	Number of Subjects
1	R I	R II	T	5
2	R I	T	R II	5
3	R II	R I	T	5
4	R II	T	R I	5
5	T	R I	R II	5
6	T	R II	R I	5

Abbreviations: R I, reference I (bazedoxifene 20 mg); R II, reference II (cholecalciferol 1600 IU); T, test (bazedoxifene 20 mg + cholecalciferol 1600 IU).

D content. Between two consecutive periods, there was a washout period of at least 14 days. These subjects were admitted to the Clinical Trial Center at Asan Medical Center (Seoul, Korea) the day before drug administration. The test drugs were administered orally under fasting conditions with 150 mL of water. After receiving the investigational drug(s), subjects were required to fast for four hours. Depending on the treatment, subjects were discharged on either day 2 (bazedoxifene monotherapy) or day 6 (cholecalciferol monotherapy or combined therapy). A follow-up visit was scheduled two weeks after the last dose.

To determine the plasma bazedoxifene concentration, serial blood samples were collected at 0 (pre-dose), 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72, 96, and 120 hours after the dosing. To measure the baseline cholecalciferol level, blood samples were collected at 16, 12, 8, and 0 hours before the cholecalciferol dosing, and the average concentration for each individual was used as the baseline cholecalciferol concentration. Baseline-adjusted cholecalciferol concentrations were obtained by subtracting the baseline from the post-dose plasma cholecalciferol concentrations measured at 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 48, 72, 96 and 120 hours after the treatment. If the baseline-adjusted cholecalciferol concentration had a negative value, zero was assigned.

Blood samples used for the drug concentration measurements were drawn into ethylenediaminetetraacetic acid K₂ tubes. Plasma was separated by centrifugation at 1800 × g for 8 minutes at 4 °C and stored in Eppendorf tubes at -70 °C until analysis. At the analytical laboratory (BioCore Co. Ltd., Seoul, Korea), samples were thawed at room temperature. The plasma concentrations of bazedoxifene and cholecalciferol were assayed using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS). Bazedoxifene samples were prepared by liquid-liquid extraction, and cholecalciferol samples by protein precipitation and solid-phase extraction. Liquid chromatography was conducted using a Shimadzu UFLC system (Shimadzu Corp., Kyoto, Japan). For tandem mass spectrometry, a SCIEX TQ5500 mass spectrometer (AB Sciex LLC, MA, USA) was used. The calibration curves covered the ranges of 0.1–20 ng/mL for bazedoxifene and 0.1–10 ng/mL for cholecalciferol. For bazedoxifene, the accuracy of LC-MS/MS was 91.8–113.0%, and the precision was 0.1–5.5%. For cholecalciferol, the accuracy of LC-MS/MS was 92.7–105.6%, and the precision was 0.2–4.5%. The lower limit of quantification was 0.1 ng/mL for both compounds.

The study protocol was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB number: 2017–0227) and by the Korean Ministry of Food and Drug Safety. The study was registered at ClinicalTrials.gov (NCT03089112). All subjects provided written informed consent before receiving screening tests. All study procedures were conducted in accordance with the ethical principles stated in the Declaration of Helsinki and by the Good Clinical Practice Guidelines of the International Council for Harmonisation.^{9,10} The study was conducted from March 31, 2017 to June 16, 2017.

Pharmacokinetic Analysis

The PK parameters of bazedoxifene and cholecalciferol in each subject were analyzed by the non-compartmental method using Phoenix WinNonlin[®] version 6.4 (Certara, NJ, USA). This analysis was based on the actual sampling time. The maximum plasma concentration (C_{max}) and the time to reach C_{max} (T_{max}) were determined from the observed values. The terminal elimination rate constant (λ_z) was estimated by linear regression analysis of the terminal portion of the semilogarithmic concentration-time curve. The terminal elimination half-life ($t_{1/2\beta}$) was calculated as the natural log of two divided by λ_z . Demographic data and PK parameters were summarized using descriptive statistics. The C_{max} and the values for the area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC_{last}) were log-transformed to compare the drug exposure between the combined therapy and monotherapy. The point estimate and 90% confidence interval (CI) for the geometric mean ratio (GMR) of the combined therapy to monotherapy were obtained for C_{max} and AUC_{last} .

Safety and Tolerability Assessment

Safety and tolerability were assessed throughout the study by physical examinations, laboratory tests (complete blood count, blood chemistry, and urinalysis), 12-lead ECG, and monitoring of adverse events (AEs). AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA[®] version 19.1) and recorded in terms of symptom/sign, onset, duration, severity, relationship to the investigational drug(s), action taken, and outcome.

Results

Study Participants

Of the 30 study participants who received the investigational drug(s) at least once, 27 subjects completed the study (Figure 1). Two subjects withdrew their consent to participate, and one subject was excluded at the investigator's discretion due to a medical need for concomitant medication that could potentially affect the PK data. Participant demographics, including age, weight, height, and BMI, are summarized in Table 2. The mean \pm standard deviation (SD) values were 28.63 ± 4.18 years for age, 71.53 ± 6.99 kg for weight, 173.55 ± 4.80 cm for height, and 23.75 ± 2.09 kg/m² for BMI. All subjects who received the investigational drug(s) at least once were included in the safety and tolerability assessment.

Pharmacokinetic Findings

The 27 subjects who completed the study were included in the PK analysis set, and the PK parameters are presented in Table 3. For bazedoxifene, the C_{\max} values (mean \pm SD) for monotherapy and combined therapy were 3.30 ± 0.92 ng/mL and 3.62 ± 1.39 ng/mL, respectively. The AUC_{last} values (mean \pm SD) for monotherapy and combined therapy were 44.32 ± 22.24 h·ng/mL and 50.78 ± 24.98 h·ng/mL, respectively. The mean plasma concentration-time profiles of bazedoxifene for monotherapy and combined therapy nearly overlapped (Figure 2A). For bazedoxifene, the GMR (90% CI) of the combined therapy to monotherapy was 1.044 (0.9263–1.1765) for C_{\max} and 1.1329 (1.0232–1.2544) for AUC_{last} (Table 4).

For baseline-adjusted cholecalciferol, the C_{\max} values (mean \pm SD) for monotherapy and combined therapy were 2.25 ± 0.47 ng/mL and 1.95 ± 0.54 ng/mL, respectively. The AUC_{last} values (mean \pm SD) for monotherapy and combined therapy were 59.43 ± 22.95 h·ng/mL and 49.18 ± 24.40 h·ng/mL, respectively. The mean plasma concentration-time profiles of baseline-adjusted cholecalciferol for monotherapy and combined therapy are shown in Figure 2B. For baseline-adjusted




Figure 1 Subject disposition.

Table 2 Demographic Characteristics of the Participants (n=30)

		Sequence						Total
		1	2	3	4	5	6	
Number of Subjects		5	5	5	5	5	5	30
Age (years)	Mean	27.20	29.00	29.20	28.20	30.60	27.60	28.63
	SD	6.30	6.20	2.17	3.42	3.44	3.29	4.18
Weight (kg)	Mean	70.57	71.25	75.24	71.78	70.61	69.74	71.53
	SD	11.17	8.53	7.15	4.93	6.17	4.47	6.99
Height (cm)	Mean	177.40	174.04	174.20	171.28	172.80	171.58	173.55
	SD	5.44	4.43	4.83	5.26	4.83	3.50	4.80
BMI (kg/m²)	Mean	22.36	23.44	24.76	24.46	23.72	23.74	23.75
	SD	2.46	2.13	1.91	1.21	2.69	2.04	2.09

Abbreviations: BMI, body mass index; SD, standard deviation.

Table 3 Pharmacokinetic Parameters of Bazedoxifene and Baseline-Adjusted Cholecalciferol in Healthy Male Subjects (n=27)

Parameter	Bazedoxifene		Baseline-Adjusted Cholecalciferol	
	Bazedoxifene	Bazedoxifene + Cholecalciferol	Cholecalciferol	Bazedoxifene + Cholecalciferol
AUC_{last} (h · ng/mL)	44.32 (22.24)	50.78 (24.98)	59.43 (22.95)	49.18 (24.40)
C_{max} (ng/mL)	3.30 (0.92)	3.62 (1.39)	2.25 (0.47)	1.95 (0.54)
t_{1/2β} (h)	26.67 (30.03)	24.56 (10.03)	13.39 (3.16)	13.89 (5.60)
T_{max}* (h)	2.00 [1.00–6.00]	1.53 [1.00–6.00]	11.98 [8.00–14.02]	12.00 [8.00–14.07]

Notes: Data are presented as mean values (standard deviation) except for T_{max}. *Median [minimum - maximum].

Abbreviations: AUC_{last}, area under the plasma concentration-time curve from time zero to the last quantifiable concentration; C_{max}, maximum plasma concentration; t_{1/2β}, terminal elimination half-life; T_{max}, time to reach C_{max}.

cholecalciferol, the GMR (90% CI) of combined therapy to monotherapy was 0.8543 (0.8005–0.9117) for C_{max} and 0.8056 (0.7445–0.8717) for AUC_{last} (Table 4).

Safety and Tolerability Findings

Seventeen subjects showed a total of 26 AEs after drug administration (Table 5). No serious AE occurred throughout the entire study. All AEs were mild in severity and resolved without any sequelae. The most common AE was




Figure 2 Mean plasma concentration-time curves: (A) bazedoxifene (B) baseline-adjusted cholecalciferol. The error bars denote standard deviations.

Table 4 Geometric Mean Ratios of Combined Therapy to Monotherapy for AUC_{last} and C_{max}

Parameter	GMR	90% Confidence Interval		Test	Reference
		Lower Limit	Upper Limit		
Bazedoxifene (n=27)					
C _{max} (ng/mL)	1.044	0.9263	1.1765	Bazedoxifene + Cholecalciferol	Bazedoxifene
AUC _{last} (h · ng/mL)	1.1329	1.0232	1.2544	Bazedoxifene + Cholecalciferol	Bazedoxifene
Baseline-adjusted Cholecalciferol (n=27)					
C _{max} (ng/mL)	0.8543	0.8005	0.9117	Bazedoxifene + Cholecalciferol	Cholecalciferol
AUC _{last} (h · ng/mL)	0.8056	0.7445	0.8717	Bazedoxifene + Cholecalciferol	Cholecalciferol

Abbreviations: AUC_{last}, area under the plasma concentration-time curve from time zero to the last quantifiable concentration; C_{max}, maximum plasma concentration; GMR, geometric mean ratio.

nasopharyngitis (five events in five subjects). Clinically significant findings from the physical examination were phlebitis of the arm and venipuncture site bruise. Clinically significant laboratory abnormalities included increased blood levels of creatine phosphokinase and triglyceride and decreased blood levels of neutrophil count. No clinically significant abnormalities were found with respect to vital signs and 12-lead ECG. Twenty-five AEs were considered to have no or unlikely relationship with the investigational drugs. One AE, fatigue observed after combined therapy, was considered to have a possible relationship with the administered drugs.

Table 5 Adverse Events in the Study Population After Drug Administration

Adverse Event	Treatment			Total (n=30)
	Bazedoxifene (n=30)	Cholecalciferol (n=28)	Bazedoxifene + Cholecalciferol (n=27)	
Eye pain	1 (3.33%)/1	0	0	1 (3.33%)/1
Vomiting	1 (3.33%)/1	0	0	1 (3.33%)/1
Fatigue	0	0	1 (3.70%)/1	1 (3.33%)/1
Vessel puncture site bruise	1 (3.33%)/1	1 (3.57%)/1	0	2 (6.67%)/2
Nasopharyngitis	1 (3.33%)/1	1 (3.57%)/1	3 (11.11%)/3	5 (16.67%)/5
Pyuria	0	1 (3.57%)/1	0	1 (3.33%)/1
Muscle injury	0	0	2 (7.41%)/2	2 (6.67%)/2
Contusion	0	1 (3.57%)/1	0	1 (3.33%)/1
Blood creatine phosphokinase increased	2 (6.67%)/2	2 (7.14%)/2	0	4 (13.33%)/4
Blood triglycerides increased	2 (6.67%)/2	1 (3.57%)/1	0	3 (10.00%)/3
Neutrophil count decreased	1 (3.33%)/1	1 (3.57%)/1	1 (3.70%)/1	2 (6.67%)/3
Epistaxis	0	1 (3.57%)/1	0	1 (3.33%)/1
Phlebitis	1 (3.33%)/1	0	0	1 (3.33%)/1
Total	6 (20.00%)/10	9 (32.14%)/9	6 (20.22%)/7	17 (56.67%)/26

Notes: Data are presented as the number of subjects with adverse events (percentage)/number of adverse events. A subject was counted once if the subject reported one or more adverse events. Percentages are based on the total number of subjects in each column (n).

Discussion

This study investigated the PK characteristics of bazedoxifene and cholecalciferol, their PK interactions, and the safety and tolerability of combined therapy with these drugs in healthy male subjects.

The terminal elimination half-life of bazedoxifene was approximately 27 hours, and that of cholecalciferol was 13 hours in our study. The washout period of 14 days should therefore have been sufficient for both investigational drugs to be fully eliminated by the next period. The blood samples obtained up to 120 hours after dosing provided sufficient information for characterizing the exposures to bazedoxifene and cholecalciferol.

Previous studies on bazedoxifene pharmacokinetics have indicated a T_{max} of 1–2 hours and a half-life of approximately 28 hours.¹¹ As shown in Figure 2 and Table 3, bazedoxifene was rapidly absorbed when administered alone or in combination with cholecalciferol, showing median T_{max} values of 2.00 h and 1.53 h, respectively. The T_{max} of cholecalciferol is known to be approximately 15 hours. In our study, the median T_{max} of cholecalciferol was 11.98 h when administered alone, similar to the 12.00 h value found for its co-administration with bazedoxifene.

In a recent study on bazedoxifene, the mean C_{max} and AUC_{last} in healthy male subjects after a single 20 mg oral dose were 3.191 ng/mL and 44.697 h·ng/mL, respectively.¹² These numbers are consistent with the results of the current study (3.30 ng/mL and 44.32 h·ng/mL). The PK parameters C_{max} and AUC_{last} were used in our analyses to compare the combined therapy and monotherapy exposures. With bazedoxifene, the 90% CI for the GMR of the combined therapy to bazedoxifene monotherapy for C_{max} fell within the 0.80–1.25 range, and for AUC_{last} it was nearly within the above-mentioned range.

In the case of cholecalciferol, the AUC_{last} was lower when this drug was co-administered with bazedoxifene, as indicated by the GMR of 0.8056 and associated 90% CI of 0.7445–0.8717. Bazedoxifene and cholecalciferol are drugs that exhibit wide therapeutic ranges.^{13–15} Cholecalciferol is known to reach a sigmoidal dose-response curve plateau at a dose of 600 IU.¹⁵ Hence, based on the GMRs observed in our exploratory study, the difference in the AUC_{last} for cholecalciferol is unlikely to have clinical significance in treatment efficacy at the dose level used in our protocol.

All of the AEs observed in our study population were mild, and the frequency of AEs in subjects who received combined therapy was not significantly different from that in subjects who received monotherapy. The most common AE observed in our present trial cohort was nasopharyngitis, which we considered unrelated to the investigational drugs.

One limitation of the present study was that the participants were all healthy men. The study was exploratory in nature, and male subjects were included to facilitate enrollment and minimize health risks to subjects. Drug-drug interaction studies are often conducted with male subjects, and the results are applied to women as well as men because gender does not seem to affect the pattern of drug-drug interaction for many drugs. Assuming that the PK interactions would follow the same pattern in men and women, this study was conducted in men instead of women. Additional studies in postmenopausal women with osteoporosis and patients with different pathophysiological conditions will help further characterize the PK interactions between bazedoxifene and cholecalciferol.

Conclusion

The combined therapy of 20 mg bazedoxifene (one tablet) and 1600 IU cholecalciferol (two tablets of 800 IU) was safe and well tolerated in healthy male subjects. In this present study, the oral co-administration of bazedoxifene with cholecalciferol tended to decrease the cholecalciferol exposure slightly. Considering that both drugs have wide therapeutic ranges, dose adjustment of cholecalciferol may not be necessary for its co-administration with bazedoxifene.

Abbreviations

AE, adverse event; AUC_{last} , area under the concentration-time curve from time zero to the last quantifiable concentration; BMI, body mass index; CI, confidence interval; C_{max} , maximum plasma concentration; ECG, electrocardiogram; GMR, geometric mean ratio; IRB, Institutional Review Board; LC-MS/MS, liquid chromatography with tandem mass spectrometry; λ_z , terminal elimination rate constant; PK, pharmacokinetic; SD, standard deviation; SERM, selective estrogen receptor modulator; T_{max} , time to reach C_{max} ; $t_{1/2\beta}$, terminal elimination half-life.

Data Sharing Statement

The authors do not intend to share individual de-identified participant data of this study due to confidentiality.

Funding

This study was sponsored by Hanmi Pharmaceutical Co. Ltd.

Disclosure

Hyeong-Seok Lim has received grants from Hanmi Pharmaceutical Co. Ltd. for a range of research projects, including the study reported in this article. Jina Jung and Sung Hee Hong are employees of Hanmi Pharmaceutical Co. Ltd. The remaining authors declare no competing interests in relation to this article.

References

1. Cosman F, de Beur SJ, LeBoff MS, et al. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2
2. Rejnmark L, Mosekilde L. New and emerging antiresorptive treatments in osteoporosis. *Curr Drug Saf*. 2011;6(2):75–88. doi:10.2174/157488611795684686
3. Song H, Li X, Zhao Z, et al. Reversal of osteoporotic activity by endothelial cell-secreted bone targeting and biocompatible exosomes. *Nano Lett*. 2019;19(5):3040–3048. doi:10.1021/acs.nanolett.9b00287
4. Zeng ZL, Xie H. Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review. *Biomater Transl*. 2022;3(3):175–187. doi:10.12336/biomatertransl.2022.03.002
5. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. *Endocrinology*. 2005;146(9):3999–4008. doi:10.1210/en.2005-0030
6. Stump AL, Kelley KW, Wensel TM. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. *Ann Pharmacother*. 2007;41(5):833–839. doi:10.1345/aph.1H428
7. Conbriza. European medicines agency; 2009. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza>. Accessed October 21, 2022.
8. DUAVEE. *Drug Label (NDA 022247)*. Silver Spring, MD: US Food and Drug Administration; 2013.
9. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
10. Guideline for Good Clinical Practice E6(R2). International council for harmonisation of technical requirements for pharmaceuticals for human use; 2016. Available from: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed October 21, 2022.
11. Gatti D, Rossini M, Sblendorio I, Lello S. Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. *Expert Opin Drug Metab Toxicol*. 2013;9(7):883–892. doi:10.1517/17425255.2013.794221
12. Yeun JS, Kan HS, Lee M, et al. Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers. *Transl Clin Pharmacol*. 2020;28(2):102–108. doi:10.12793/tcp.2020.28.e7
13. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. *Menopause*. 2009;16(6):1109–1115. doi:10.1097/gme.0b013e3181a818db
14. Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. *Clin Interv Aging*. 2011;6:151–160. doi:10.2147/CIA.S15711
15. Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: The National Academies Press; 2011.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>